These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 11956647)

  • 1. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
    Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
    Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
    Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
    Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
    Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer.
    Mantovani G; Macciò A; Lai P; Massa E; Massa D; Mulas C; Succu G; Mudu MC; Manca G; Versace R; Pisano A
    J Immunother; 2000; 23(2):267-74. PubMed ID: 10746553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer.
    Ozawa Y; Inui N; Naitoh T; Yasuda K; Nagayama M; Shirai T; Suganuma H; Fujii M; Nakamura H; Suda T; Chida K
    Lung Cancer; 2009 Jan; 63(1):68-71. PubMed ID: 18513824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
    Kim YS; Yoon SM; Choi EK; Yi BY; Kim JH; Ahn SD; Lee SW; Shin SS; Lee JS; Suh C; Kim SW; Kim DS; Kim WS; Park HJ; Park CI
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):76-81. PubMed ID: 15850905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
    Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
    Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study.
    Cigolari S; Curcio C; Maiorino A; Sessa R; Cioffi A; Massimo M
    Anticancer Res; 2003; 23(2C):1803-9. PubMed ID: 12820462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
    Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
    Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
    Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.
    Planchard D; Bourgeois H; Adoun M; Paitel JF; Blanc P; Genet D; Ferru A; Meurice JC; Deletage C; Tourani JM
    Am J Clin Oncol; 2006 Aug; 29(4):345-51. PubMed ID: 16891860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
    Ichinose Y; Yoshimori K; Sakai H; Nakai Y; Sugiura T; Kawahara M; Niitani H
    Clin Cancer Res; 2004 Dec; 10(23):7860-4. PubMed ID: 15585618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
    Mantovani G; Proto E; Massa E; Mulas C; Madeddu C; Mura L; Mudu MC; Astara G; Murgia V; Gramignano G; Ferreli L; Camboni P; Lusso MR; Mocci M; Tore G; Mura M; Amichetti M; Maccio A
    Int J Oncol; 2002 Feb; 20(2):419-27. PubMed ID: 11788911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.